We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+46.36%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$7.86B
AUM Growth
+$1.46B
Cap. Flow
+$137M
Cap. Flow %
1.74%
Top 10 Hldgs %
51.1%
Holding
83
New
21
Increased
18
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$142M
2
DYN icon
Dyne Therapeutics
DYN
+$112M
3
EVH icon
Evolent Health
EVH
+$102M
4
LENZ
LENZ Therapeutics
LENZ
+$86.9M
5
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$71.7M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$704M
2
CBAY
Cymabay Therapeutics
CBAY
+$164M
3
ICVX
Icosavax, Inc. Common Stock
ICVX
+$94M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$93.6M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$76.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
2 Miscellaneous 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
51
Boundless Bio
BOLD
$63.9M
$31.1M 0.4%
+2,180,631
New +$31.1M
MGNX icon
52
MacroGenics
MGNX
$257M
$30.6M 0.39%
2,082,021
-1,971,056
-49% -$29.8M
TNYA icon
53
Tenaya Therapeutics
TNYA
$150M
$30.1M 0.38%
5,755,050
+247,703
+4% +$1.19M
HELP
54
Cybin Inc
HELP
$959M
$24M 0.31%
+1,529,988
New +$22.1M
ANRO icon
55
Alto Neuroscience
ANRO
$1.19B
$21.3M 0.27%
+1,385,491
New +$21.7M
CRVO icon
56
CervoMed
CRVO
$37M
$20.1M 0.26%
+861,573
New +$11.5M
VXRT
57
DELISTED
Vaxart
VXRT
$20M 0.25%
+15,384,615
New +$16.1M
BCYC
58
Bicycle Therapeutics
BCYC
$257M
$19.9M 0.25%
800,000
– –
EYPT icon
59
EyePoint Inc
EYPT
$316M
$19.4M 0.25%
+938,591
New +$23.2M
THRD
60
DELISTED
Third Harmonic Bio
THRD
$19.2M 0.24%
2,033,056
– –
PLRX icon
61
Pliant Therapeutics
PLRX
$69.4M
$19.1M 0.24%
1,281,000
– –
SERA icon
62
Sera Prognostics
SERA
$78.5M
$18.4M 0.23%
+2,024,221
New +$16M
MGX icon
63
Metagenomi Therapeutics
MGX
$43.8M
$18.4M 0.23%
+1,744,415
New +$20.1M
IMTX icon
64
Immatics
IMTX
$1.31B
$18.4M 0.23%
+1,750,000
New +$20.4M
ANTX icon
65
AN2 Therapeutics
ANTX
$202M
$18M 0.23%
5,551,295
– –
RGLS
66
DELISTED
Regulus Therapeutics
RGLS
$18M 0.23%
+6,250,000
New +$10.2M
BDTX icon
67
Black Diamond Therapeutics
BDTX
$113M
$17.9M 0.23%
3,525,754
– –
ACET icon
68
Adicet Bio
ACET
$79.7M
$17.7M 0.23%
+471,313
New +$19.5M
ARVN icon
69
Arvinas
ARVN
$540M
$17.4M 0.22%
421,348
– –
LXEO icon
70
Lexeo Therapeutics
LXEO
$339M
$10.4M 0.13%
+660,938
New +$10.3M
CMRX
71
DELISTED
Chimerix, Inc.
CMRX
$9.33M 0.12%
8,800,000
– –
IGMS
72
DELISTED
IGM Biosciences
IGMS
$9.05M 0.12%
937,500
– –
CMPS
73
Compass Pathways
CMPS
$1.91B
$6.58M 0.08%
791,359
-494,641
-38% -$4.98M
CVAC
74
DELISTED
CureVac
CVAC
$5.96M 0.08%
1,965,707
-778,563
-28% -$2.73M
UNCY icon
75
Unicycive Therapeutics
UNCY
$131M
$4.79M 0.06%
347,069
– –
1 2
3
4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, RA Capital Management held 83 positions worth $7.86B, up 23% from $6.4B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RA Capital Management's Q1 2024 filing shows 21 new, 18 increased, 5 reduced and 7 closed positions. Its largest new stake was Edgewise Therapeutics: 8,909,091 shares worth $163M. The largest sale was Immunogen Inc, an estimated $704M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • RA Capital Management's largest Q1 2024 buy was Edgewise Therapeutics: 8,909,091 shares worth $163M.
  • RA Capital Management added most to Evolent Health in Q1 2024, an estimated $102M increase.
  • RA Capital Management's biggest Q1 2024 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $76.4M.
  • RA Capital Management fully exited Immunogen Inc in Q1 2024, selling an estimated $704M.
  • RA Capital Management's ten largest holdings make up 51% of its $7.86B portfolio in Q1 2024.
  • RA Capital Management opened 21 new positions and closed 7 in Q1 2024.
  • RA Capital Management's portfolio value rose 23% quarter-over-quarter to $7.86B.

Based on RA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.